Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Radiotherapy for liver cancer, and neoadjuvant therapy for rectal cancer

SLAGO 2019

Published: 17 Jul 2019

Views: 1462

Rating:

Save

Dr Parag Parikh - Mayo Clinic, Rochester, USA

Dr Parag Parikh speaks to ecancer at the SLAGO 2019 meeting in Chile about stereotactic radiation for liver cancer, and neoadjuvant therapy for rectal cancer.

Dr Parikh overviews both of his presentations, including treatment options and their placement in the clinical landscape of Latin America.

He finalises by describing the most important steps to take in Latin America to help with treatment.

Related Videos

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India

Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Lung Cancer

Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India

Lung Cancer ( Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India )

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

More from ecancer